Gregory Harriman

Venture Partner

Dr. Gregory Harriman is an accomplished physician, scientist and biomedical executive having over 25 years of experience with increasing responsibilities in academic medicine and the biopharmaceutical industry. He has held leadership positions in both small and large biopharmaceutical companies, having global responsibilities in research and development of pharmaceuticals, biologics, medical devices and cell therapies, which has given him a thorough understanding of the requirements for development of drugs, biologics and cell therapies, from discovery through regulatory submissions. He has led successful regulatory submissions in the U.S. (both NDAs and BLAs), EU (MAAs) and Japan (NDAs) and has presented to FDA Advisory Committees and the EMEA. In previous positions at IVAX, Centocor and J&J, he led clinical R&D groups responsible for development of both drugs and biologics, including Remicade┬« (infliximab) for treatment of rheumatoid arthritis, Crohn’s disease and other immune-mediated diseases, which has current annual sales in excess of $5 billion.

Dr. Harriman founded Main Line Ventures, an investment and consultancy company focused on identifying innovative and pioneering life sciences opportunities. He is a member of Robin Hood Ventures, an angel investing group, and he works closely with the life sciences community in the Philadelphia area to identify and fund biotech companies and to advance translational medical research. He is a research professor at Drexel and an advisor to its Coulter Translational Medicine Program which provides funding for therapeutic, medical device or diagnostic projects that have significant potential to be successfully developed and commercialized. He was previously on the Board of Directors at Novira, a biotech company developing viral capsid inhibitors for hepatitis B and HIV.

He attended the University of California, Berkeley as an undergraduate and received his medical degree at the University of California, San Diego. He trained in internal medicine at Barnes Hospital and completed a fellowship in infectious diseases at the NIH. He is board-certified in internal medicine, infectious diseases and clinical & laboratory immunology. He had a successful academic career at the NIH and Baylor College of Medicine, publishing over 40 scientific papers, obtaining R01 and U01 grant funding from the NIH as well as private foundation funding, and conducting innovative research in immunology, vaccines and immune-mediated diseases. He is a fellow of the American College of Physicians and is a member of several other professional medical organizations.


Other Team Members